27 results on '"Tomassoni L"'
Search Results
2. Plasticity in adult Dclk1+ intestinal neuronal and glial cells facilitates regeneration and ganglionic cellular homeostasis
- Author
-
Middelhoff, M, additional, Valenti, G, additional, Tomassoni, L, additional, Laise, P, additional, Takahashi, R, additional, Nienhüser, H, additional, Finlayson, M, additional, Belin, B, additional, Renz, B, additional, Westphalen, B, additional, Quante, M, additional, Sims, P, additional, Califano, A, additional, Rao, M, additional, Gershon, M, additional, and Wang, T, additional
- Published
- 2020
- Full Text
- View/download PDF
3. Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia
- Author
-
Flenghi L, Fagioli M, Tomassoni L, Pileri S, Gambacorta M, Pacini R, Grignani F, Casini T, Pier Francesco Ferrucci, and Mf, Martelli
- Subjects
Cytoplasm ,Oncogene Proteins, Fusion ,Receptors, Retinoic Acid ,Molecular Sequence Data ,Promyelocytic Leukemia Protein ,Transfection ,Epithelium ,Monocytes ,Birds ,Epitopes ,Mice ,Species Specificity ,Transforming Growth Factor beta ,Chlorocebus aethiops ,Tumor Cells, Cultured ,Animals ,Humans ,Amino Acid Sequence ,Cell Line, Transformed ,Cholecalciferol ,Cell Nucleus ,Mammals ,Mice, Inbred BALB C ,Macrophages ,Retinoic Acid Receptor alpha ,Tumor Suppressor Proteins ,Antibodies, Monoclonal ,Nuclear Proteins ,Epithelial Cells ,3T3 Cells ,Macrophage Activation ,Peptide Fragments ,Neoplasm Proteins ,Gene Expression Regulation ,Endothelium, Vascular ,Rabbits ,Transcription Factors - Abstract
PG-M3 is a new monoclonal antibody (MoAb) specifically directed against a peptide sequence located in the aminoterminal region of the human PML protein. PML gene fuses with the retinoic acid receptor alpha (RAR alpha) gene during the t(15; 17) chromosomal translocation of acute promyelocytic leukemia (APL). The epitope recognized by PG-M3 is species-specific and fixative-resistant and is shared by most PML isoforms and PML/RAR alpha fusion proteins. PML is consistently located within the nucleus, although a minority of cells (about 20%), both in vitro and in vivo, show positivity for PML also in the cytoplasm. The nuclear staining pattern of PG-M3 varies from speckled (cells other than APL) to micropunctate (APL cells). Although two physiologically expressed PML isoforms are detectable by immunocytochemistry only or predominantly in the cytoplasm of transfected cells, the cytoplasmic localization of PML is a property also shared by the PML isoforms that predominantly localize to the nuclei. Immunohistologic analysis of normal human tissues with the PG-M3 MoAb showed variable PML expression, with the highest levels of the protein in postmitotic, differentiated cell types, such as endothelial cells, epithelia, and tissue macrophages, especially activated ones. In keeping with this in vivo finding, PML appears strongly upregulated in the U937 promonocyte cell line after exposure to agents that induce monocyte/macrophage activation (interferon gamma) or maturation (vitamin D3 and transforming growth factor beta 1).
- Published
- 1995
4. CHARACTERIZATION OF A NEW MONOCLONAL ANTIBODY (PG-M3) DIRECTED AGAINST THE AMINOTERMINAL PORTION OF THE PML GENE PRODUCT: IMMUNOCYTOCHEMICAL EVIDENCE FOR HIGH EXPRESSION OF PML PROTEINS ON ACTIVATED MACROPHAGES, ENDOTHELIAL CELLS, AND EPITHELIA
- Author
-
Flenghi, L, Fagioli, M, Tomassoni, L, Pileri, S, Gambacorta, M, Pelicci, Pg, and Falini, Brunangelo
- Published
- 1995
5. Cellular localization and tissue distribution of PML proteins as defined by a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product. Preferential expression in postmitotic cells
- Author
-
Flenghi, L., Fagioli, M., Tomassoni, L., Pileri, S., Pacini, R., Grignani, Francesco, Casini, T., Ferrucci, P. F., Martelli, Massimo Fabrizio, Pelicci, P. G., and Falini, Brunangelo
- Subjects
Leukemia ,PML ,diagnosis ,monoclonal antibodies - Published
- 1995
6. Pathogenetic Relevance Of The Acute Promyelocytic Leukemia-Specific PML/RARa Fusion Protein
- Author
-
Grignani, Francesco, Fagioli, M., Alcalay, M., Ferrucci, Pf, Tomassoni, L., Rogaia, Daniela, Liberatore, Concetta, Ruthardt, M., Mencarelli, Amedea, Grignani, Fausto, and Pelicci, P. G.
- Subjects
Leukemia ,PML/RAR ,Oncogenes - Published
- 1994
7. Molecular Pathogenesis of Acute Promyelocytic Leukaemia
- Author
-
Grignani, Francesco, Fagioli, M., Alcalay, M., Tomassoni, L., Rogaia, Daniela, Grignani, Fausto, and Pelicci, Pg
- Subjects
Leukemia ,Oncogenes ,PML/RAR ,Retinoic Acid - Published
- 1994
8. Molecular Genetics Of The T(15;17) Of Acute Promyelocytic Leukemia
- Author
-
Alcalay, M., Fagioli, M., Grignani, Francesco, Ferrucci, Pf, Tomassoni, L., Rogaia, Daniela, Liberatore, Concetta, Ruthardt, M., Mencarelli, Amedea, Grignani, Fausto, and Pelicci, Pg
- Subjects
Leukemia ,PML/RAR ,Oncogenes ,Genetics - Published
- 1994
9. The molecular genetics of acute promyelocytic leukemia
- Author
-
Grignani, Francesco, Fagioli, M., Alcalay, M., Ferrucci, P. F., Tomassoni, L., Rogaia, D., Grignani, F., and Pelicci, P. G.
- Subjects
leukemia ,Oncogenes - Published
- 1993
10. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein.
- Author
-
Alcalay, M, Tomassoni, L, Colombo, E, Stoldt, S, Grignani, F, Fagioli, M, Szekely, L, Helin, K, Pelicci, P G, Alcalay, M, Tomassoni, L, Colombo, E, Stoldt, S, Grignani, F, Fagioli, M, Szekely, L, Helin, K, and Pelicci, P G
- Abstract
Udgivelsesdato: 1998-Feb, PML is a nuclear protein with growth-suppressive properties originally identified in the context of the PML-retinoic acid receptor alpha (RAR alpha) fusion protein of acute promyelocytic leukemia. PML localizes within distinct nuclear structures, called nuclear bodies, which are disrupted by the expression of PML-RAR alpha. We report that PML colocalizes with the nonphosphorylated fraction of the retinoblastoma protein (pRB) within nuclear bodies and that pRB is delocalized by PML-RAR alpha expression. Both PML and PML-RAR alpha form complexes with the nonphosphorylated form of pRB in vivo, and they interact with the pocket region of pRB. The regions of PML and PML-RAR alpha involved in pRB binding differ; in fact, the B boxes and the C-terminal region of PML, the latter of which is not present in PML-RAR alpha, are essential for the formation of stable complexes with pRB. Functionally, PML abolishes activation of glucocorticoid receptor-regulated transcription by pRB, whereas PML-RAR alpha further increases it. Our results suggest that PML may be part of transcription-regulatory complexes and that the oncogenic potential of the PML-RAR alpha protein may derive from the alteration of PML-regulated transcription.
- Published
- 1998
11. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
- Author
-
Wasko UN, Jiang J, Dalton TC, Curiel-Garcia A, Edwards AC, Wang Y, Lee B, Orlen M, Tian S, Stalnecker CA, Drizyte-Miller K, Menard M, Dilly J, Sastra SA, Palermo CF, Hasselluhn MC, Decker-Farrell AR, Chang S, Jiang L, Wei X, Yang YC, Helland C, Courtney H, Gindin Y, Muonio K, Zhao R, Kemp SB, Clendenin C, Sor R, Vostrejs WP, Hibshman PS, Amparo AM, Hennessey C, Rees MG, Ronan MM, Roth JA, Brodbeck J, Tomassoni L, Bakir B, Socci ND, Herring LE, Barker NK, Wang J, Cleary JM, Wolpin BM, Chabot JA, Kluger MD, Manji GA, Tsai KY, Sekulic M, Lagana SM, Califano A, Quintana E, Wang Z, Smith JAM, Holderfield M, Wildes D, Lowe SW, Badgley MA, Aguirre AJ, Vonderheide RH, Stanger BZ, Baslan T, Der CJ, Singh M, and Olive KP
- Published
- 2024
- Full Text
- View/download PDF
12. Identification and Targeting of Regulators of SARS-CoV-2-Host interactions in the Airway Epithelium.
- Author
-
Dirvin B, Noh H, Tomassoni L, Cao D, Zhou Y, Ke X, Qian J, Schotsaert M, García-Sastre A, Karan C, Califano A, and Cardoso WV
- Abstract
Although the impact of SARS-CoV-2 in the lung has been extensively studied, the molecular regulators and targets of the host-cell programs hijacked by the virus in distinct human airway epithelial cell populations remain poorly understood. This is in part ascribed to the use of non-primary cell systems, overreliance on single-cell gene expression profiling that not ultimately reflect protein activity and bias toward the downstream effects rather than their mechanistic determinants. Here we address these issues by network-based analysis of single cell transcriptomic profiles of pathophysiologically relevant human adult basal, ciliated and secretory cells to identify master regulator (MR) protein modules controlling their SARS-CoV-2-mediated reprogramming. This uncovered chromatin remodeling, endosomal sorting, ubiquitin pathway as well as proviral factors identified by CRISPR analyses as components of the host response collectively or selectively activated in these cells. Large-scale perturbation assays, using a clinically-relevant drug library, identified 11 drugs able to invert the entire MR signature activated by SARS-CoV-2 in these cell types. Leveraging MR analysis and perturbational profiles of human primary cells, represents a novel mechanism-based approach and resource that can be directly generalized to interrogate signatures of other airway conditions for drug prioritization., Competing Interests: DECLARATION OF INTERESTS Dr. Califano is founder, equity holder, and consultant of DarwinHealth Inc., a company that has licensed some of the algorithms used in this manuscript from Columbia University. Columbia niversity is also an equity holder in DarwinHealth Inc. Lorenzo Tomassoni is an employee of DarwinHealth Inc.
- Published
- 2024
- Full Text
- View/download PDF
13. Targeted delivery of napabucasin with radiotherapy improves outcomes in diffuse midline glioma.
- Author
-
Gallitto M, Zhang X, De Los Santos G, Wei HJ, Fernández EC, Duan S, Sedor G, Yoh N, Kokosi D, Angel JC, Wang YF, White E, Kinslow CJ, Berg X, Tomassoni L, Zandkarimi F, Chio IIC, Canoll PD, Bruce JN, Feldstein NA, Gartrell RD, Cheng S, Garvin JH, Zacharoulis S, Wechsler-Reya RJ, Pavisic J, Califano A, Zhang Z, and Wu CC
- Abstract
Background: Diffuse midline glioma (DMG) is the most aggressive primary brain tumor in children. All previous studies examining the role of systemic agents have failed to demonstrate a survival benefit; the only standard of care is radiation therapy (RT). Successful implementation of radiosensitization strategies in DMG remains an essential and promising avenue of investigation. We explore the use of Napabucasin, an NAD(P)H quinone dehydrogenase 1 (NQO1)-bioactivatable reactive oxygen species (ROS)-inducer, as a potential therapeutic radiosensitizer in DMG., Methods: In this study, we conduct in vitro and in vivo assays using patient-derived DMG cultures to elucidate the mechanism of action of Napabucasin and its radiosensitizing properties. As penetration of systemic therapy through the blood-brain barrier (BBB) is a significant limitation to the success of DMG therapies, we explore focused ultrasound (FUS) and convection-enhanced delivery (CED) to overcome the BBB and maximize therapeutic efficacy., Results: Napabucasin is a potent ROS-inducer and radiosensitizer in DMG, and treatment-mediated ROS production and cytotoxicity are dependent on NQO1. In subcutaneous xenograft models, combination therapy with RT improves local control. After optimizing targeted drug delivery using CED in an orthotopic mouse model, we establish the novel feasibility and survival benefit of CED of Napabucasin concurrent with RT., Conclusions: As nearly all DMG patients will receive RT as part of their treatment course, our validation of the efficacy of radiosensitizing therapy using CED to prolong survival in DMG opens the door for exciting novel studies of alternative radiosensitization strategies in this devastating disease while overcoming limitations of the BBB., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
14. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.
- Author
-
Wasko UN, Jiang J, Dalton TC, Curiel-Garcia A, Edwards AC, Wang Y, Lee B, Orlen M, Tian S, Stalnecker CA, Drizyte-Miller K, Menard M, Dilly J, Sastra SA, Palermo CF, Hasselluhn MC, Decker-Farrell AR, Chang S, Jiang L, Wei X, Yang YC, Helland C, Courtney H, Gindin Y, Muonio K, Zhao R, Kemp SB, Clendenin C, Sor R, Vostrejs WP, Hibshman PS, Amparo AM, Hennessey C, Rees MG, Ronan MM, Roth JA, Brodbeck J, Tomassoni L, Bakir B, Socci ND, Herring LE, Barker NK, Wang J, Cleary JM, Wolpin BM, Chabot JA, Kluger MD, Manji GA, Tsai KY, Sekulic M, Lagana SM, Califano A, Quintana E, Wang Z, Smith JAM, Holderfield M, Wildes D, Lowe SW, Badgley MA, Aguirre AJ, Vonderheide RH, Stanger BZ, Baslan T, Der CJ, Singh M, and Olive KP
- Subjects
- Animals, Female, Humans, Mice, Apoptosis drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Disease Models, Animal, DNA Copy Number Variations, Drug Resistance, Neoplasm drug effects, Genes, myc, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local genetics, Treatment Outcome, Xenograft Model Antitumor Assays, Mutation, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal pathology, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal metabolism, Guanosine Triphosphate metabolism, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology, Pancreatic Neoplasms genetics, Pancreatic Neoplasms metabolism, Proto-Oncogene Proteins p21(ras) genetics, Proto-Oncogene Proteins p21(ras) metabolism, Proto-Oncogene Proteins p21(ras) antagonists & inhibitors
- Abstract
Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS mutations
1,2 . RMC-7977 is a highly selective inhibitor of the active GTP-bound forms of KRAS, HRAS and NRAS, with affinity for both mutant and wild-type variants3 . More than 90% of cases of human pancreatic ductal adenocarcinoma (PDAC) are driven by activating mutations in KRAS4 . Here we assessed the therapeutic potential of RMC-7977 in a comprehensive range of PDAC models. We observed broad and pronounced anti-tumour activity across models following direct RAS inhibition at exposures that were well-tolerated in vivo. Pharmacological analyses revealed divergent responses to RMC-7977 in tumour versus normal tissues. Treated tumours exhibited waves of apoptosis along with sustained proliferative arrest, whereas normal tissues underwent only transient decreases in proliferation, with no evidence of apoptosis. In the autochthonous KPC mouse model, RMC-7977 treatment resulted in a profound extension of survival followed by on-treatment relapse. Analysis of relapsed tumours identified Myc copy number gain as a prevalent candidate resistance mechanism, which could be overcome by combinatorial TEAD inhibition in vitro. Together, these data establish a strong preclinical rationale for the use of broad-spectrum RAS-GTP inhibition in the setting of PDAC and identify a promising candidate combination therapeutic regimen to overcome monotherapy resistance., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF
15. Elucidation and Pharmacologic Targeting of Master Regulator Dependencies in Coexisting Diffuse Midline Glioma Subpopulations.
- Author
-
Fernández EC, Tomassoni L, Zhang X, Wang J, Obradovic A, Laise P, Griffin AT, Vlahos L, Minns HE, Morales DV, Simmons C, Gallitto M, Wei HJ, Martins TJ, Becker PS, Crawford JR, Tzaridis T, Wechsler-Reya RJ, Garvin J, Gartrell RD, Szalontay L, Zacharoulis S, Wu CC, Zhang Z, Califano A, and Pavisic J
- Abstract
Diffuse Midline Gliomas (DMGs) are universally fatal, primarily pediatric malignancies affecting the midline structures of the central nervous system. Despite decades of clinical trials, treatment remains limited to palliative radiation therapy. A major challenge is the coexistence of molecularly distinct malignant cell states with potentially orthogonal drug sensitivities. To address this challenge, we leveraged established network-based methodologies to elucidate Master Regulator (MR) proteins representing mechanistic, non-oncogene dependencies of seven coexisting subpopulations identified by single-cell analysis-whose enrichment in essential genes was validated by pooled CRISPR/Cas9 screens. Perturbational profiles of 372 clinically relevant drugs helped identify those able to invert the activity of subpopulation-specific MRs for follow-up in vivo validation. While individual drugs predicted to target individual subpopulations-including avapritinib, larotrectinib, and ruxolitinib-produced only modest tumor growth reduction in orthotopic models, systemic co-administration induced significant survival extension, making this approach a valuable contribution to the rational design of combination therapy.
- Published
- 2024
- Full Text
- View/download PDF
16. Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression.
- Author
-
Hasselluhn MC, Decker-Farrell AR, Vlahos L, Thomas DH, Curiel-Garcia A, Maurer HC, Wasko UN, Tomassoni L, Sastra SA, Palermo CF, Dalton TC, Ma A, Li F, Tolosa EJ, Hibshoosh H, Fernandez-Zapico ME, Muir A, Califano A, and Olive KP
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Cell Proliferation, Hedgehog Proteins genetics, Vascular Endothelial Growth Factor A, Carcinoma, Pancreatic Ductal pathology, Pancreatic Neoplasms pathology
- Abstract
The sparse vascularity of pancreatic ductal adenocarcinoma (PDAC) presents a mystery: What prevents this aggressive malignancy from undergoing neoangiogenesis to counteract hypoxia and better support growth? An incidental finding from prior work on paracrine communication between malignant PDAC cells and fibroblasts revealed that inhibition of the Hedgehog (HH) pathway partially relieved angiosuppression, increasing tumor vascularity through unknown mechanisms. Initial efforts to study this phenotype were hindered by difficulties replicating the complex interactions of multiple cell types in vitro. Here we identify a cascade of paracrine signals between multiple cell types that act sequentially to suppress angiogenesis in PDAC. Malignant epithelial cells promote HH signaling in fibroblasts, leading to inhibition of noncanonical WNT signaling in fibroblasts and epithelial cells, thereby limiting VEGFR2-dependent activation of endothelial hypersprouting. This cascade was elucidated using human and murine PDAC explant models, which effectively retain the complex cellular interactions of native tumor tissues., Significance: We present a key mechanism of tumor angiosuppression, a process that sculpts the physiologic, cellular, and metabolic environment of PDAC. We further present a computational and experimental framework for the dissection of complex signaling cascades that propagate among multiple cell types in the tissue environment. This article is featured in Selected Articles from This Issue, p. 201., (©2023 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
17. Socioeconomic and Racial/Ethnic Disparities in Recovery from Childhood Behavioral or Conduct Problems: Evidence from a Nationally Representative Sample of 3-17 Years Old US Children.
- Author
-
Khanijahani A and Tomassoni L
- Subjects
- Adolescent, Child, Child, Preschool, Humans, Black People, Hispanic or Latino, Income, Poverty, United States epidemiology, Child Behavior Disorders diagnosis, Child Behavior Disorders ethnology, Child Behavior Disorders therapy, White, Emigrants and Immigrants, Socioeconomic Factors, Race Factors, Black or African American, Racial Groups
- Abstract
Our study provides nationally-generalizable evidence on the racial/ethnic and socioeconomic disparities in diagnosis and recovery from childhood behavioral or conduct problems. We pooled data from 4 years (2016-2019) of the National Survey of Children's Health (NSCH) for 3 to 17 years old US children (N = 114,476). We performed several logistic regression models using complex survey data analysis statistical methodologies to estimate nationally representative and generalizable results in the Stata MP 16 program. About 20.1% of 3-17 years old US children previously diagnosed with behavioral or conduct problems no longer had the current diagnosis (were recovered). Hispanic children [Odds ratio (OR) 0.77, 95% Confidence Interval (CI) 0.65-0-95], immigrant children or children of immigrant parents (first or second generation immigrant children), and children from high-income families [200-399% Federal Poverty Level (FPL)] were about 23%, 38%, and 21% less likely than non-Hispanic White children, children of US native parents, and children with a family income of below 100% FPL to be currently diagnosed with behavioral or conduct problems, respectively. Conversely, Non-Hispanic Black and Hispanic children were about 50% and 40% more likely than non-Hispanic White children to recover from a past diagnosis. Moreover, children from higher-income families (at or above 300% of FPL) were between 1.59 to 1.79 times more likely than those from low-income families (below 100% FPL) to recover from a past diagnosis. Racial/ethnic and socioeconomic disparities in diagnosing appear to persist in recovering from behavioral or conduct problems., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
18. Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators.
- Author
-
Obradovic A, Ager C, Turunen M, Nirschl T, Khosravi-Maharlooei M, Iuga A, Jackson CM, Yegnasubramanian S, Tomassoni L, Fernandez EC, McCann P, Rogava M, DeMarzo AM, Kochel CM, Allaf M, Bivalacqua T, Lim M, Realubit R, Karan C, Drake CG, and Califano A
- Subjects
- Humans, Proteins metabolism, Lymphocytes, Tumor-Infiltrating metabolism, Repressor Proteins metabolism, T-Lymphocytes, Regulatory metabolism, Neoplasms drug therapy, Neoplasms genetics, Neoplasms metabolism
- Abstract
Due to their immunosuppressive role, tumor-infiltrating regulatory T cells (TI-Tregs) represent attractive immuno-oncology targets. Analysis of TI vs. peripheral Tregs (P-Tregs) from 36 patients, across four malignancies, identified 17 candidate master regulators (MRs) as mechanistic determinants of TI-Treg transcriptional state. Pooled CRISPR-Cas9 screening in vivo, using a chimeric hematopoietic stem cell transplant model, confirmed the essentiality of eight MRs in TI-Treg recruitment and/or retention without affecting other T cell subtypes, and targeting one of the most significant MRs (Trps1) by CRISPR KO significantly reduced ectopic tumor growth. Analysis of drugs capable of inverting TI-Treg MR activity identified low-dose gemcitabine as the top prediction. Indeed, gemcitabine treatment inhibited tumor growth in immunocompetent but not immunocompromised allografts, increased anti-PD-1 efficacy, and depleted MR-expressing TI-Tregs in vivo. This study provides key insight into Treg signaling, specifically in the context of cancer, and a generalizable strategy to systematically elucidate and target MR proteins in immunosuppressive subpopulations., Competing Interests: Declaration of interests C.G.D. is a co-inventor on patents licensed from JHU to BMS and Janssen; has served as a paid consultant to AZ Medimmune, BMS, Pfizer, Roche, Sanofi Aventis, Genentech, Merck, and Janssen; and has received sponsored research funding to his institution from BMS IioN and Janssen. A.C. is founder, equity holder, consultant, and director of DarwinHealth, Inc., which has licensed IP related to these algorithms from Columbia University. Columbia University is an equity holder in DarwinHealth, Inc. S.Y. has received sponsored research support to his institution from Celgene/BMS, Janssen, and Cepheid/Danaher and has served as a paid consultant to Cepheid/Danaher. A.O., C.A., C.G.D., and A.C. are co-inventors on US provisional patent no. 63/188,970, “Therapeutic modulation of regulatory T cells through master regulatory protein targeting,” which relates to the work described here., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
19. Adult enteric Dclk1-positive glial and neuronal cells reveal distinct responses to acute intestinal injury.
- Author
-
Middelhoff M, Valenti G, Tomassoni L, Ochiai Y, Belin B, Takahashi R, Malagola E, Nienhüser H, Finlayson M, Hayakawa Y, Zamechek LB, Renz BW, Westphalen CB, Quante M, Margolis KG, Sims PA, Laise P, Califano A, Rao M, Gershon MD, and Wang TC
- Subjects
- Animals, Integrin alpha2 metabolism, Mice, Mice, Transgenic, Neuroglia metabolism, Neurons metabolism, Enteric Nervous System physiology, Neural Stem Cells
- Abstract
Intestinal ganglionic cells in the adult enteric nervous system (ENS) are continually exposed to stimuli from the surrounding microenvironment and need at times to respond to disturbed homeostasis following acute intestinal injury. The kinase DCLK1 and intestinal Dclk1-positive cells have been reported to contribute to intestinal regeneration. Although Dclk1-positive cells are present in adult enteric ganglia, their cellular identity and response to acute injury have not been investigated in detail. Here, we reveal the presence of distinct Dclk1-tdTom+/CD49b+ glial-like and Dclk1-tdTom+/CD49b- neuronal cell types in adult myenteric ganglia. These ganglionic cells demonstrate distinct patterns of tracing over time yet show a similar expansion in response to elevated serotonergic signaling. Interestingly, Dclk1-tdTom+ glial-like and neuronal cell types appear resistant to acute irradiation injury-mediated cell death. Moreover, Dclk1-tdTom+/CD49b+ glial-like cells show prominent changes in gene expression profiles induced by injury, in contrast to Dclk1-tdTom+/CD49b- neuronal cell types. Finally, subsets of Dclk1-tdTom+/CD49b+ glial-like cells demonstrate prominent overlap with Nestin and p75NTR and strong responses to elevated serotonergic signaling or acute injury. These findings, together with their role in early development and their neural crest-like gene expression signature, suggest the presence of reserve progenitor cells in the adult Dclk1 glial cell lineage. NEW & NOTEWORTHY The kinase DCLK1 identifies glial-like and neuronal cell types in adult murine enteric ganglia, which resist acute injury-mediated cell death yet differ in their cellular response to injury. Interestingly, Dclk1-labeled glial-like cells show prominent transcriptional changes in response to injury and harbor features reminiscent of previously described enteric neural precursor cells. Our data thus add to recently emerging evidence of reserve cellular plasticity in the adult enteric nervous system.
- Published
- 2022
- Full Text
- View/download PDF
20. Socioeconomic and Racial Segregation and COVID-19: Concentrated Disadvantage and Black Concentration in Association with COVID-19 Deaths in the USA.
- Author
-
Khanijahani A and Tomassoni L
- Subjects
- Health Status Disparities, Humans, Residence Characteristics, SARS-CoV-2, Socioeconomic Factors, United States epidemiology, COVID-19, Social Segregation
- Abstract
Introduction: This study's objective was to examine the association of the percentage of county population residing in concentrated disadvantage and Black-concentrated census tracts with county-level confirmed COVID-19 deaths in the USA, concentrated disadvantage and Black concentration at census tract-level measure socioeconomic segregation and racial segregation, respectively., Methods: We performed secondary data analysis using tract (N = 73,056) and county (N = 3142) level data from the US Census Bureau and other sources for the USA. Confirmed COVID-19 deaths per 100,000 population was our outcome measure. We performed mixed-effect negative binomial regression to examine the association of county population's percentage residing in concentrated disadvantage and Black-concentrated tracts with COVID-19 deaths while controlling for several other characteristics., Results: For every 10% increase in the percentage of county population residing in concentrated disadvantage and Black-concentrated tracts, the rate for confirmed COVID-19 deaths per 100,000 population increases by a factor of 1.14 (mortality rate ratio [MMR] = 1.14; 95% confidence interval [CI]:1.11, 1.18) and 1.11 (MMR = 1.11; 95% CI:1.08, 1.14), respectively. These relations stayed significant in all models in further sensitivity analyses. Moreover, a joint increase in the percentage of county population residing in racial and socioeconomic segregation was associated with a much greater increase in COVID-19 deaths., Conclusions: It appears that people living in socioeconomically and racially segregated neighborhoods may be disproportionately impacted by COVID-19 deaths. Future multilevel and longitudinal studies with data at both individual and aggregated tract level can help isolate the potential impacts of the individual-level characteristics and neighborhood-level socioeconomic and racial segregation with more precision and confidence., (© 2021. W. Montague Cobb-NMA Health Institute.)
- Published
- 2022
- Full Text
- View/download PDF
21. Application of conditional robust calibration to ordinary differential equations models in computational systems biology: a comparison of two sampling strategies.
- Author
-
Bianconi F, Antonini C, Tomassoni L, and Valigi P
- Subjects
- Calibration, Models, Biological, Systems Biology
- Abstract
Mathematical modelling is a widely used technique for describing the temporal behaviour of biological systems. One of the most challenging topics in computational systems biology is the calibration of non-linear models; i.e. the estimation of their unknown parameters. The state-of-the-art methods in this field are the frequentist and Bayesian approaches. For both of them, the performance and accuracy of results greatly depend on the sampling technique employed. Here, the authors test a novel Bayesian procedure for parameter estimation, called conditional robust calibration (CRC), comparing two different sampling techniques: uniform and logarithmic Latin hypercube sampling. CRC is an iterative algorithm based on parameter space sampling and on the estimation of parameter density functions. They apply CRC with both sampling strategies to the three ordinary differential equations (ODEs) models of increasing complexity. They obtain a more precise and reliable solution through logarithmically spaced samples.
- Published
- 2020
- Full Text
- View/download PDF
22. CRA toolbox: software package for conditional robustness analysis of cancer systems biology models in MATLAB.
- Author
-
Bianconi F, Antonini C, Tomassoni L, and Valigi P
- Subjects
- Animals, Computer Simulation, Disease Models, Animal, ErbB Receptors metabolism, Humans, Kinetics, Male, Mice, Organ Specificity, PTEN Phosphohydrolase deficiency, PTEN Phosphohydrolase metabolism, Prostate metabolism, Receptor, IGF Type 1 metabolism, Signal Transduction, Algorithms, Models, Biological, Neoplasms metabolism, Software, Systems Biology methods
- Abstract
Background: In cancer research, robustness of a complex biochemical network is one of the most relevant properties to investigate for the development of novel targeted therapies. In cancer systems biology, biological networks are typically modeled through Ordinary Differential Equation (ODE) models. Hence, robustness analysis consists in quantifying how much the temporal behavior of a specific node is influenced by the perturbation of model parameters. The Conditional Robustness Algorithm (CRA) is a valuable methodology to perform robustness analysis on a selected output variable, representative of the proliferation activity of cancer disease., Results: Here we introduce our new freely downloadable software, the CRA Toolbox. The CRA Toolbox is an Object-Oriented MATLAB package which implements the features of CRA for ODE models. It offers the users the ability to import a mathematical model in Systems Biology Markup Language (SBML), to perturb the model parameter space and to choose the reference node for the robustness analysis. The CRA Toolbox allows the users to visualize and save all the generated results through a user-friendly Graphical User Interface (GUI). The CRA Toolbox has a modular and flexible architecture since it is designed according to some engineering design patterns. This tool has been successfully applied in three nonlinear ODE models: the Prostate-specific Pten
-/- mouse model, the Pulse Generator Network and the EGFR-IGF1R pathway., Conclusions: The CRA Toolbox for MATLAB is an open-source tool implementing the CRA to perform conditional robustness analysis. With its unique set of functions, the CRA Toolbox is a remarkable software for the topological study of biological networks. The source and example code and the corresponding documentation are freely available at the web site: http://gitlab.ict4life.com/SysBiOThe/CRA-Matlab .- Published
- 2019
- Full Text
- View/download PDF
23. Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study.
- Author
-
Ludovini V, Chiari R, Tomassoni L, Antonini C, Baldelli E, Baglivo S, Siggillino A, Tofanetti FR, Bellezza G, Hodge KA, Petricoin E, Pierobon M, Crinò L, and Bianconi F
- Abstract
In this work high throughput technology and computational analysis were used to study two stage IV lung adenocarcinoma patients treated with standard chemotherapy with markedly different survival (128 months vs 6 months, respectively) and whose tumor samples exhibit a dissimilar protein activation pattern of the signal transduction. Tumor samples of the two patients were subjected to Reverse Phase Protein Microarray (RPPA) analysis to explore the expression/activation levels of 51 signaling proteins. We selected the most divergent proteins based on the ratio of their RPPA values in the two patients with short (s-OS) and long (l-OS) overall survival (OS) and tested them against a EGFR-IGF1R mathematical model. The model with RPPA data showed that the activation levels of 19 proteins were different in the two patients. The four proteins that most distinguished the two patients were BADS155/136 and c-KITY703/719 having a higher activation level in the patient with short survival and p70S6S371/T389 and b-RAFS445 that had a lower activation level in the s-OS patient. The final model describes the interactions between the MAPK and PI3K-mTOR pathways, including 21 nodes. According to our model mTOR and ERK activation levels were predicted to be lower in the s-OS patient than the l-OS patient, while the AMPK activation level was higher in the s-OS patient. Moreover, KRAS activation was predicted to be higher in the l-OS KRAS -mutated patient. In accordance with their different biological properties, the Moment Independent Robustness Indicator in s-OS and l-OS predicted the interaction of MAPK and mTOR and the crosstalk AKT with p90RSK as candidates to be prognostic factors and drug targets., Competing Interests: CONFLICTS OF INTEREST The authors declare that they have no competing interests.
- Published
- 2017
- Full Text
- View/download PDF
24. Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival.
- Author
-
Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli A, Riganelli D, Grignani F, Pozzan T, Nicoletti I, Grignani F, and Pelicci PG
- Subjects
- 3T3 Cells, Animals, Binding Sites, Cell Division, Cell Line, Transformed, Cell Survival, Cysteine genetics, Cysteine physiology, Cytoplasm metabolism, HeLa Cells, Histidine genetics, Histidine physiology, Humans, Isomerism, Mice, Mutagenesis, Neoplasm Proteins genetics, Promyelocytic Leukemia Protein, Transcription Factors genetics, Tumor Cells, Cultured, Tumor Suppressor Proteins, Zinc Fingers genetics, Apoptosis, Neoplasm Proteins physiology, Nuclear Proteins, Transcription Factors physiology, Zinc Fingers physiology
- Abstract
PML/RARalpha is the abnormal protein product of the Acute Promyelocytic Leukemia-specific 15;17 translocation. Both the PML and RARalpha components are required for the PML/RARalpha biological activities, namely its capacity to block differentiation and to increase survival of haematopoietic precursors. The physiological role of PML and its contribution to the function of the fusion protein are unknown. PML localizes to the cytoplasm and within specific nuclear bodies (NBs). In vitro, overexpression of PML correlates with suppression of cell transformation. The PML aminoterminal portion retained within the PML/RARalpha protein contains the RING finger, two newly defined cystein/histidine-rich motifs called B-boxes (B1 and B2) and a coiled-coil region. We report here that PML has a growth suppressive activity in all the cell lines tested, regardless of their transformed phenotype, and that the cellular basis for the PML growth suppression is induction of apoptotic cell death. Analysis of various nuclear and cytoplasmic PML isoforms showed that the PML growth suppressive activity correlates with its nuclear localization. Analysis of the localization and growth suppressive activity demonstrated that: (i) the Ring + B1-B2 and coiled-coil regions are both indispensable and sufficient to target PML to the NBs; (ii) individual deletions of the various PML domains have no effect on its growth suppressor activity; (iii) the Ring + B1-B2 region exerts a partial growth suppressor activity but its fusion with the coiled-coil region is sufficient to recapitulate the suppressive function of wild type PML. These results indicate that PML is involved in cell survival regulation and that the PML component of the fusion protein (Ring + B1-B2 and coiled-coil regions) retains intact biological activity, thereby suggesting that the effects of PML/RARalpha on survival derive from the activation of the incorporated PML sequence.
- Published
- 1998
- Full Text
- View/download PDF
25. The acute promyelocytic leukaemia specific PML and PLZF proteins localize to adjacent and functionally distinct nuclear bodies.
- Author
-
Ruthardt M, Orleth A, Tomassoni L, Puccetti E, Riganelli D, Alcalay M, Mannucci R, Nicoletti I, Grignani F, Fagioli M, and Pelicci PG
- Subjects
- Fluorescent Antibody Technique, Humans, Kruppel-Like Transcription Factors, Promyelocytic Leukemia Protein, Promyelocytic Leukemia Zinc Finger Protein, Receptors, Retinoic Acid analysis, Recombinant Fusion Proteins analysis, Retinoic Acid Receptor alpha, Tumor Cells, Cultured, Tumor Suppressor Proteins, Cell Nucleus chemistry, DNA-Binding Proteins analysis, Neoplasm Proteins analysis, Nuclear Proteins analysis, Transcription Factors analysis
- Abstract
Acute promyelocytic leukaemia is characterized by translocations that involve the retinoic acid receptor alpha (RAR alpha) locus on chromosome 17 and the PML locus on 15 or the PLZF locus on 11. The resulting abnormal translocation products encode for PML/RAR alpha or PLZF/RAR alpha fusion proteins. There is increasing experimental evidence that the APL-specific fusion proteins have similar biologic activities on differentiation and survival and that both components of the fusion proteins (PML or PLZF and RAR alpha) are indispensable for these biological activities. The physiologic function of PML or PLZF or whether PML and PLZF contribute common structural or functional features to the corresponding fusion proteins is not known. We report here immunofluorescence studies on the cellular localization of PLZF and PLZF/RAR alpha and compare it with the localization of PML and PML/RAR alpha. PLZF localizes to nuclear domains of 0.3-0.5 microns, approximately 14 per cell in the KG1 myeloid cell line. These PLZF-bodies are morphologically similar to the domains reported for PML (PML-NBs). There is tight spatial relationship between about 30% of PLZ-NBs and PML-NBs: they partially overlap. However, PML and PLZF do not form soluble complexes in vivo. PLZF- and PML-NBs are functionally distinct. Adenovirus E4-ORF3 protein expression alters the structure of the PML-NBs and interferon increases the number of PML-NBs and neither has any effect on PLZF NBs. The localization of PLZF/RAR alpha is different to that of PLZF and RAR alpha. The nuclear distribution pattern of PLZF/RAR alpha is one of hundreds of small dots (microspeckles) less than 0.1 micron. Expression of PLZF/RAR alpha did not provoke disruption of the PML-NBs. Co-expression of PML/RAR alpha and PLZF/RAR alpha in U937 cells revealed apparent colocalization. Overall the results suggest that the PML- and PLZF-NBs are distinct functional nuclear domains, but that they may share common regulatory pathways and/or targeting sequences, as revealed by the common localization of their corresponding fusion proteins.
- Published
- 1998
- Full Text
- View/download PDF
26. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
- Author
-
Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, and Pelicci PG
- Subjects
- Binding Sites, Cell Differentiation drug effects, Cell Differentiation physiology, Cell Line, Cloning, Molecular, DNA-Binding Proteins genetics, Enzyme Inhibitors pharmacology, Gene Expression Regulation, Neoplastic, Histone Deacetylase Inhibitors, Histone Deacetylases genetics, Hydroxamic Acids pharmacology, Leukemia, Promyelocytic, Acute genetics, Leukemia, Promyelocytic, Acute metabolism, Mutagenesis, Neoplasm Proteins genetics, Nuclear Proteins genetics, Nuclear Proteins physiology, Nuclear Receptor Co-Repressor 1, Oncogene Proteins, Fusion genetics, Protein Binding, Receptors, Retinoic Acid genetics, Repressor Proteins genetics, Repressor Proteins physiology, Retinoic Acid Receptor alpha, Transcription Factors genetics, Tretinoin pharmacology, Tumor Suppressor Proteins, DNA-Binding Proteins physiology, Histone Deacetylases physiology, Leukemia, Promyelocytic, Acute enzymology, Neoplasm Proteins physiology, Oncogene Proteins, Fusion physiology, Receptors, Retinoic Acid physiology, Transcription Factors physiology
- Abstract
The transforming proteins of acute promyelocytic leukaemias (APL) are fusions of the promyelocytic leukaemia (PML) and the promyelocytic leukaemia zinc-finger (PLZF) proteins with retinoic acid receptor-alpha (RARalpha). These proteins retain the RARalpha DNA- and retinoic acid (RA)-binding domains, and their ability to block haematopoietic differentiation depends on the RARalpha DNA-binding domain. Thus RA-target genes are downstream effectors. However, treatment with RA induces differentiation of leukaemic blast cells and disease remission in PML-RARalpha APLs, whereas PLZF-RARa APLs are resistant to RA. Transcriptional regulation by RARs involves modifications of chromatin by histone deacetylases, which are recruited to RA-target genes by nuclear co-repressors. Here we show that both PML-RARalpha and PLZF-RARalpha fusion proteins recruit the nuclear co-repressor (N-CoR)-histone deacetylase complex through the RARalpha CoR box. PLZF-RARalpha contains a second, RA-resistant binding site in the PLZF amino-terminal region. High doses of RA release histone deacetylase activity from PML-RARalpha, but not from PLZF-RARalpha. Mutation of the N-CoR binding site abolishes the ability of PML-RARalpha to block differentiation, whereas inhibition of histone deacetylase activity switches the transcriptional and biological effects of PLZF-RARalpha from being an inhibitor to an activator of the RA signalling pathway. Therefore, recruitment of histone deacetylase is crucial to the transforming potential of APL fusion proteins, and the different effects of RA on the stability of the PML-RARalpha and PLZF-RARalpha co-repressor complexes determines the differential response of APLs to RA.
- Published
- 1998
- Full Text
- View/download PDF
27. The promyelocytic leukemia gene product (PML) forms stable complexes with the retinoblastoma protein.
- Author
-
Alcalay M, Tomassoni L, Colombo E, Stoldt S, Grignani F, Fagioli M, Szekely L, Helin K, and Pelicci PG
- Subjects
- Cell Division, Humans, Inclusion Bodies metabolism, Macromolecular Substances, Neoplasm Proteins genetics, Promoter Regions, Genetic, Promyelocytic Leukemia Protein, Protein Binding, Receptors, Glucocorticoid metabolism, Transcription Factors genetics, Transcription, Genetic, Tumor Cells, Cultured, Tumor Suppressor Proteins, Neoplasm Proteins metabolism, Nuclear Proteins, Oncogene Proteins, Fusion metabolism, Retinoblastoma Protein metabolism, Transcription Factors metabolism
- Abstract
PML is a nuclear protein with growth-suppressive properties originally identified in the context of the PML-retinoic acid receptor alpha (RAR alpha) fusion protein of acute promyelocytic leukemia. PML localizes within distinct nuclear structures, called nuclear bodies, which are disrupted by the expression of PML-RAR alpha. We report that PML colocalizes with the nonphosphorylated fraction of the retinoblastoma protein (pRB) within nuclear bodies and that pRB is delocalized by PML-RAR alpha expression. Both PML and PML-RAR alpha form complexes with the nonphosphorylated form of pRB in vivo, and they interact with the pocket region of pRB. The regions of PML and PML-RAR alpha involved in pRB binding differ; in fact, the B boxes and the C-terminal region of PML, the latter of which is not present in PML-RAR alpha, are essential for the formation of stable complexes with pRB. Functionally, PML abolishes activation of glucocorticoid receptor-regulated transcription by pRB, whereas PML-RAR alpha further increases it. Our results suggest that PML may be part of transcription-regulatory complexes and that the oncogenic potential of the PML-RAR alpha protein may derive from the alteration of PML-regulated transcription.
- Published
- 1998
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.